Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PhytaGenics Inc.

Latest From PhytaGenics Inc.

PhytaGenics Inc.

PhytaGenics is using transgenic technology to produce high-value pharmaceutical proteins and bulk enzymes in the leaves of potato plants as well as other species, under greenhouse conditions.
BioPharmaceutical Manufacturing

Protein Harvest

Genetic engineering is giving a new meaning to the term "manufacturing plant" as the biotechnology industry looks to potatoes, corn, tobacco, and other crops to provide cheap manufacturing sources for therapeutic The lack of capacity for the cost-effective manufacture of protein-based pharmaceuticals will soon cause a significant bottleneck at pharmaceutical companies, one that threatens to impede the progress of therapeutics at all stages of development, from the preclinical stage to commercialization. Today, companies are faced with the limited options of either queuing up for outsourced manufacturing, or investing hundreds of millions of dollars in their own production capacity well before they know that a product will succeed. A bumper crop of new companies is therefore poised to take advantage of the manufacturing capabilities of plants that have been genetically engineered to produce human proteins.
BioPharmaceutical Manufacturing

Start-Up Previews (05/01)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Protein Harvest, features profiles of Meristem Therapeutics; MPB Cologne GMBH; PhytaGenics Inc. and ProdiGene Inc. Plus these selected Start-Ups across Health Care: Gentris Corp.; HemoGenix LLC; Psychiatric Genomics Inc. and Zassi Medical Evolutions Inc.

Selected Start-Ups (02/01)

In Vivo summarizes the technology of several recently founded companies: Clinsights Inc. provides web-based post-market clinical and sales support for medical device and pharmaceutical companies and physicians. CombinatoRx Inc. hopes to develop the next generation of pharmaceuticals using new theories of how therapeutics should interact with the complex components of cells. Gyros AB has developed technology for miniaturizing and integrating routine and non-routine laboratory processes on disposable CDs. Innovative Drug Delivery Systems Inc. will develop and commercialize unique nasally administered compounds to treat acute and chronic pain and their associated symptoms. PhytaGenics will use its proprietary rapid, high-volume transgenic production technology to create recombinant biopharmaceutical proteins in plants. StemCo Biomedical Inc.'s stem cell platform is capable of identifying and isolating healthy stem cells from contaminating cells, and can be used in repopulating blood systems or regenerating organs and tissue.
See All

Company Information

  • Industry
  • Biotechnology
  • Biotechnology
    • Synthesis Technologies, Production Processes
    • Transgenics
  • Pharmaceuticals
  • Therapeutic Areas
  • Alias(es)
  • PhytaGenics
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • PhytaGenics Inc.
  • Senior Management
  • Rick Srigley, Pres. & CEO
    Nicholas J Lombardo, Dir., Bus. Dev.
  • Contact Info
  • PhytaGenics Inc.
    Phone: (509) 375-3644
    260 Cochrane Circle
    Ste. E
    Morgan Hill, CA 95037